



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/196,161	11/20/1998	YOKE MIN SIN	1459-005B	8822

22429 7590 09/06/2002

LOWE HAUPTMAN GILMAN AND BERNER, LLP
1700 DIAGONAL ROAD
SUITE 300 /310
ALEXANDRIA, VA 22314

EXAMINER

MINNIFIELD, NITA M

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 09/06/2002

36

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/196,161

Applicant(s)

SIN ET AL.

Examiner

N. M. Minnifield

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 June 2002.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☒ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Response to Amendment

1. Applicants' amendment filed June 10, 2002 is acknowledged and has been entered. Claims 9-23 have been canceled. Claims 1-8 are now pending in the present application. All rejections have been withdrawn in view of Applicants' amendment with the exception of those discussed below. The finality of the last Office Action has been withdrawn and a new NON-Final Office Action with new grounds of rejection is set forth below.
2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
3. The disclosure is objected to because of the following informalities: There are no figures/drawings in the application although the specification contains a section entitled "BRIEF DESCRIPTION OF THE DRAWING" (see p. 7, figures 1A, 1B, 1C, 2A, 2B). The transmittal letter with the originally filed application on November 11, 1998 does not indicate that any figures were submitted. The figure descriptions on p. 7 and any references to the figures should be deleted from the specification (see also pp. 8-10, 15, and 16). Appropriate correction is required.

This objection is maintained for the reasons of record. It is noted that the specification was objected to because there are no figures (formal or informal) found in the application file, however the specification contains a "BRIEF DESCRIPTION OF THE DRAWING" (see p. 7, figures 1A, 1B, 1C, 2A, 2B). This is

not a new matter rejection/objection. There are no drawings in the application file, nor is there any indication that any figure have been filed subsequent to filing date. If there are actual figures to be submitted, Applicant is free to do so in view of the fact that they were described in the originally filed application. Please note that should this application be passed to allowance, its publication will be delayed by printer queries from the Office of Publications because of the above situation; the Office of Publications will require that it be resolved before a patent is published.

Applicants submitted drawing on June 10, 2002, but the drawings are not of sufficient quality for the Examiner to consider. New drawings are requested.

4. The declaration filed on June 10, 2002 under 37 CFR 1.131 is sufficient to overcome the He et al (1997) reference.

5. In view of the papers filed July 10, 2002, it has been found that this nonprovisional application, as filed, through error and without deceptive intent, improperly set forth the inventorship, and accordingly, this application has been corrected in compliance with 37 CFR 1.48(a). The inventorship of this application has been changed by adding Guoliang Xu.

The application will be forwarded to the Office of Initial Patent Examination (OIPE) for issuance of a corrected filing receipt, and correction of the file jacket and PTO PALM data to reflect the inventorship as corrected.

6. The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because: It was not executed in accordance with either 37 CFR 1.66 or 1.68.

7. Claims 1, 3, 4 and 6-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Lin et al (Dev. Biol. Stand., 1997, 90:461). Library of Congress stamped date is August 21, 1997.

The claims are directed to a vaccine comprising a recombinant fusion protein, GST-iAgI, and substantially inert medium (buffer, adjuvant, immunostimulant, or carrier).

Lin et al disclose a recombinant protein, I-antigens as candidates for a recombinant subunit vaccine and indicate that the route of administration may be crucial for the development of a protective antibody response (abstract). Lin et al disclose that "fish surviving infection with the parasitic ciliate *I. multifiliis* are resistant to subsequent challenge suggesting that vaccination is possible." (abstract). Lin et al disclose that "...abundant surface membrane proteins (referred to as immobilization antigens, or I-ags) whose role in eliciting a protective response is indicated by the fact that immune fish produce parasite-immobilizing antibodies in cutaneous mucus and sera..." (abstract). Fish immunized with the i-ag had a survival rate of 25% whereas killed whole cells or crude parasite lysates did not stimulate protective immunity (abstract).

It is noted that the prior art does not specifically recite a substantially inert medium (buffer, adjuvant, immunostimulant, or carrier). However, it would be inherent that a vaccine composition would comprise a buffer, adjuvant or carrier of some kind.

Further, the prior art does not specifically recites recombinant fusion protein; but a recombinant protein is a fusion protein. The prior art anticipates the claimed invention.

Since the Patent Office does not have the facilities for examining and comparing applicants' vaccine with the vaccine of the prior art reference, the burden is upon applicants to show a distinction between the material structural and functional characteristics of the claimed vaccine and the vaccine of the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

8. Claims 2 and 5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lin et al (1997) as applied to claims 1, 3, 4 and 6-8 above, and further in view of Clark et al (PNAS, 1992, 89:6363-6367) and Smith et al (Gene, 1998, 67:31-40).

Lin et al teaches a recombinant protein, I-antigens as candidates for a recombinant subunit vaccine and indicate that the route of administration may be crucial for the development of a protective antibody response (abstract). Lin et al teaches that "fish surviving infection with the parasitic ciliate *I. multifiliis* are resistant to subsequent challenge suggesting that vaccination is possible." (abstract). Lin et al teaches that "...abundant surface membrane proteins

(referred to as immobilization antigens, or I-ags) whose role in eliciting a protective response is indicated by the fact that immune fish produce parasite-immobilizing antibodies in cutaneous mucus and sera..." (abstract). Fish immunized with the i-ag had a survival rate of 25% whereas killed whole cells or crude parasite lysates did not stimulate protective immunity (abstract).

It is noted that the prior art does not specifically recite a substantially inert medium (buffer, adjuvant, immunostimulant, or carrier). However, it would be inherent that a vaccine composition would comprise a buffer, adjuvant or carrier of some kind.

Further, the prior art does not specifically recites recombinant fusion protein; but a recombinant protein is a fusion protein.

Lin et al teaches the claimed invention except for the specific fusion protein GST-iAg and that the fusion protein is produced in *E. coli*.

However, Clark et al teaches the expression of the immobilization antigen (i.e. i-ag); the cDNA encode a protein of 394 amino acids with a tandemly repeated structure characteristic of the i-antigen of other ciliated parasites (abstract). Clark et al teaches that the immobilization antigens of *I. multifiliis* are analogous to free-living ciliates and parasitic protozoa; and "...that transcript levels increase in parallel with the infectivity of the organism bears on the functional role in this system and is consistent with previous observations suggesting that the i-antigens of *Ich* are involved in the development of protective immunity in fish. (p. 6363, col. 2; see also p. 6367, col. 2). The materials and methods teach how to obtain a recombinant immobilization antigen (p. 6363-6365).

Smith et al teach how to make and purify fusion proteins (foreign protein with GST) that have been produced in *E. coli*. (abstract; p. 38, col. 1). Smith et al teach that expression and purification of parasitic antigens (p. 33, col. 20). Smith et al teach that using GST and *E. coli* provide a better recombinant fusion protein because it avoids the difficulties of denaturing reagents altering the antigenicity and functional activity of the purified product and immunological analysis (p. 32, col. 1).

In view of the combination of references (Lin et al, Clark et al and Smith et al) it would have been obvious to a person of ordinary skill in the art at the time the invention was made to use the methods of making recombinant fusion protein (GST-iAgI) using *E. coli* to produce the recombinant fusion proteins with the reasonable expectation of success of making a vaccine comprising a recombinant fusion protein, GST-iAgI, and substantially inert medium. Lin et al teach that the antigen could be a recombinant subunit vaccine. Clark et al teach that other parasitic immobilization antigens are similar and Smith et al suggest and teach making recombinant fusion proteins (GST and a parasitic protein) and that they can be produced in *E. coli*, the same as Applicants. It would have been obvious to a person of ordinary skill in the art at the time the invention was made at to use the vaccine of Lin et al comprising the recombinant protein iAgI and adjuvant with a reasonable expectation of protecting against infection of other taxonomically related ciliated protozoan as set forth in Clark et al. Clark et al teach that other taxonomically related ciliated protozoan have the I-antigen (immobilization antigens). The claimed invention is prima facie obvious in view of the prior art absent any convincing evidence to the contrary.

9. No claims are allowed.

10. The information disclosure statement filed February 23, 1999 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each U.S. and foreign patent; each publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered.

It is noted that the copies of all of the cited references were not available to the Examiner. Please provide all cited references on the Form 1449 if Applicants desire to have them cited on an issued patent. References not initialed were not available to the Examiner.

11. The references cited or used as prior art in support of one or more rejections in the instant Office Action have been previously cited on PTO-892 mailed to Applicants on December 11, 2001 and will not be mailed again.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 703-305-3394. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette R.F. Smith can be reached on 703-308-3909. The

Application/Control Number: 09/196,161
Art Unit: 1645

Page 9


fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

N. M. Minnifield
Primary Examiner
Art Unit 1645

Nmm

August 26, 2002



NITA MINNIFIELD
PRIMARY EXAMINER